BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1248@pharmaconomics
DTSTAMP:20260707T015956Z
DTSTART;VALUE=DATE:20260327
DTEND;VALUE=DATE:20260328
SUMMARY:CANF Approval — Namodenoson
DESCRIPTION:A final FDA approval decision on Namodenoson for hepatocellular carcinoma is expected Mar 27\, 2026.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1536196/000121390026023406/ea027935901ex99-1.htm\n\nTrack it: https://pharmaconomics.com/e/1248
URL:https://pharmaconomics.com/e/1248
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:CANF catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR